Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 266-024-0 | CAS number: 65996-89-6 The condensation product obtained by cooling, to approximately ambient temperature, the gas evolved in the high temperature (greater than 700°C (1292°F)) destructive distillation of coal. A black viscous liquid denser than water. Composed primarily of a complex mixture of condensed ring aromatic hydrocarbons. May contain minor amounts of phenolic compounds and aromatic nitrogen bases.
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Carcinogenicity
Administrative data
Description of key information
In a 2-years feeding study in female B6C3F1 mice, coal tar induced tumors in lung, small intestine, and liver, as well as sarcomas, hemagiosarcomas,and histiocytic sarcomas in several sites. No tumorigenic effect was observed at a dietary level of 0.03% [approx. 36 mg/kg bw*d)], while 0.1% [approx. 120 mg/(kg bw *d)] produced significant tumours.
Key value for chemical safety assessment
Carcinogenicity: via oral route
Link to relevant study records
- Endpoint:
- carcinogenicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- comparable to guideline study
- Qualifier:
- no guideline available
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 451 (Carcinogenicity Studies)
- Deviations:
- yes
- Remarks:
- only female animals used
- Principles of method if other than guideline:
- Part of a comprehensive test programme in which the tumor profiles and DNA-adduct distribution after tar and BaP administration were compared. For comparison, single i.p. injection into infant male and female mice of two strains (B6C3F1 and A/J) and after feeding to A/J female mice were included (see results: Attached background material with only "Overall Summary Table" attached.
- GLP compliance:
- not specified
- Species:
- mouse
- Strain:
- B6C3F1
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: National Center for Toxicological Research
- Age at study initiation: 5 weeks- Weight at study initiation: 15 - 16 g (estimated from Culp et al. 1998, Fig. 1)
- Fasting period before study:
- Housing: 4/cage- Diet: ad libitum - Water: ad libitum
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.8 +-0.4
- Humidity (%): 51.7 +-1.4
- Photoperiod (hrs dark / hrs light): 12 / 12 - Route of administration:
- oral: feed
- Details on exposure:
- DIET PREPARATION
- Rate of preparation of diet (frequency): no data
- Mixing appropriate amounts with (Type of food): Coal tar frozen in liquid N2 was blended with the appropriate amount of NIH-31 meal
- Storage temperature of food: no data - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Homogeneity was verified by BaP measurement by HPLC with fluorescence detection.
- Duration of treatment / exposure:
- 2 years
- Frequency of treatment:
- continuous
- Remarks:
- Doses / Concentrations:0.01, 0.03, 0.1, 0.3, 0.6, and 1.0 % (= 0.22, 0.66, 2.2, 6.6, 13.4, and 22.0 mg BaP/kg diet)Basis:nominal in dietCTM 1
- Remarks:
- Doses / Concentrations:12, 36, 120, 360, 720, and 1200 mg/(kg bw*d)Basis:actual ingestedCTM1: estimated from food consumption and bw development
- Remarks:
- Doses / Concentrations:0.03, 0.1, and 0.3 % (= 1.1, 3.7, and 11.1 mg BaP/kg diet)Basis:nominal in dietCTM 2
- Remarks:
- Doses / Concentrations:36, 120, and 360 mg/(kg bw*d)Basis:actual ingestedCTM 2: estimated from food consumption and bw development
- No. of animals per sex per dose:
- 48
- Control animals:
- yes, concurrent no treatment
- yes, concurrent vehicle
- Positive control:
- BaP added in acetone (vehicle) to the diet: 0.0005, 0.0025, and 0.01 % (= 5, 25, and 100 mg BaP/kg diet) / estimated from food consumption and bw development: 0.6, 3, and 12 mg BaP/(kg bw*d)
- Sacrifice and pathology:
- GROSS PATHOLOGY: Yes: all mice
HISTOPATHOLOGY: Yes: liver, lungs, small intestine, stomach, tongue, and esophagus (All mice of CTM 1 groups 0.1, 0.3, 0.6 and 1.0% / all mice of the CTM 2 and BaP groups) - Other examinations:
- DNA adducts in lung, liver and forestomach, using 32P-postlabelling
- Statistics:
- Dunnett´s test applied on means of daily food consumption and organ weights including one-way analysis of variance, Kruskal-Wallis one-way analysis or Dunn´s method for comparison of organ weights of test groups vs. control group.Survival as function of the dose was calculated from the Kaplan-Meier survival curve.Tumour incidences were evaluated using methods described by Korell et al. 1983 and modified Bonferonni procedure.
- Clinical signs:
- effects observed, treatment-related
- Mortality:
- mortality observed, treatment-related
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Food efficiency:
- not specified
- Water consumption and compound intake (if drinking water study):
- not specified
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- effects observed, treatment-related
- Details on results:
- CLINICAL SIGNS AND MORTALITY (Culp et al 1998, Fig 2, not shown)
Significantly lower survival in mice exposed to both coal tar mixtures at doses of >= 0.3 % in diet [360 mg/(kg bw*d) and higher], and in mice exposed to BaP of >=22 mg/kg diet [3 mg/(kg bw*d) and higher]
BODY WEIGHT AND WEIGHT GAIN
Significantly lower body weights in mice exposed to 0.6 % and 1.0 % CTM 1 [>= 720 mg/(kg bw*d)] and to 0.3 % CTM 2 [360 mg/(kg bw*d)], and in mice exposed to BaP of 100 mg/kg diet [12 mg/(kg bw*d)]
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)CTM 1: ~25 - 30 % less at 0.6 and 1.0 %, resprectively. CTM 2: ~20 % at 0.3 %.
ORGAN WEIGHTS
Liver weights of mice fed 360 mg/(kg bw*d) CTM 1or CTM 2 (0.3 % in diet) were significantly increased, approximately 40% vs control group. Corresponding BaP doses were 0.8 and 1.1 mg/(kgbw*d), whereas treatment with 3 mg BaP/(kg bw*d) did not result in increased liver weights (Note: Liver weights of higher exposed animals not determined due to tumour development accompanied by decreases in body weights.)
HISTOPATHOLOGY: NEOPLASTIC (see Attached background material, from Culp et al 1998, Tab. III)
CTM 1: >=0.1 % [120 mg/(kg bw'd)], no significant increases in any tumor rate // >=0.3 % [360 mg/(kg bw'd)], significant and rapid increases in tumor rates (liver, lung, forestomach, hemangiosarcomas histiocytic sarcomas and sarcomas in various tissues), no increase in small intestine at 0.3 %,
CTM 2:
>=0.1 % [120 mg/(kg bw'd)], significant increase in lung tumor rate, but not in other tissues
>=0.3 % [360 mg/(kg bw'd)], significant and rapid increases in tumor rates (liver, forestomach, hemangiosarcomas histiocytic sarcomas and sarcomas in various tissues), no increase in adenosarcomas in small intestine.
>=0.6 % [720 mg/(kg bw'd)], increase in adenosarcomas in small intestine
The dose-related trends were statistically highly significant.
HISTOPATHOLOGY: NEOPLASTIC (see Attached background material, from Culp et al 1998, Tab. IV)
BaP:
at 5 mg/(kg bw*d), no significant increase in any tumour rate,
>=25 mg/(kg bw*d), significant increase in the tumour rate of the forestomach (papillomas and/or carcinomas)
at 100 mg/(kg bw*d), additionally significant increase in the tumour rates of the tongue and esophagus, insignificant of the larynx
No increases in liver, lung, and other tissues. - Dose descriptor:
- NOAEL
- Remarks:
- (= 0.03 % in diet)
- Effect level:
- ca. 36 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: neoplastic
- Dose descriptor:
- LOAEC
- Remarks:
- (= 0.1 % in diet)
- Effect level:
- ca. 120 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- histopathology: neoplastic
- Key result
- Critical effects observed:
- yes
- Lowest effective dose / conc.:
- 120 mg/kg bw/day (actual dose received)
- System:
- respiratory system: lower respiratory tract
- Organ:
- lungs
- Treatment related:
- yes
- Dose response relationship:
- yes
- Relevant for humans:
- yes
Reference
Target organs of tumorigenicity of coal tar after oral ingestion are various organs distant from the first contact point,
in particular lung and liver, while BaP-induced tumors primarily emerged in tissue of local contact.
Hence, the data indicate significant differences for tumor induction by coal tar compared to BaP
(see Goldstein et al 1998, Tab. 2, see Attached background material):
(1) Both BaP and coal tar induced forestomach tumors in the 2y feeding study.
BaP, but not coal tar, induced also tumors at two other sites, tongue and esophagus.
Coal tar, but not BaP, induced tumors in lung, small intestine, and liver, as well as sarcomas, hemagiosarcomas,
and histiocytic sarcomas in several sites.
[Note: This statement is valid for B6C3F1 mice, since BaP also induced lung tumors in A/J mice, the most sensitive strain
(see Goldstein et al., Tab. 2, see Attached background material)]
(2) Intraperitoneal single doses of 125, 250, or 375 µg BaP alone or coal tar containing 3.7 and 14.7 µg BaP induced
liver tumors in infant (15 -day old) male B6C3F1 mice, but not in females.
Lower doses of BaP (31.5 or 62.5 µg) administered i.p. alone did not induce liver tumors.
(3) Tumorigenicity in 15-day male B6C3F1 mice by coal tar could not be recapitulated by a reconstituted mixture based on component concentrations. No tumors were found when 125 µg BaP was administered as part of the reconstituted mixture,
even though BaP administered alone at 125 µg/mouse induced tumors.
(4) Ingested coal tar induced lung tumors at high incidence and high multiplicity in A/J mice.
Also high oral doses of pure BaP resulted in a limited lung tumor yield in this sensitive strain,
but much less as compared to the coal tar potency.
---------------------------
Overall, BaP is at best a weak lung carcinogen when ingested, and therefore may not be a particularly good surrogate
for the use in human health risk assessments of coal tar.
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEL
- 120 mg/kg bw/day
- Study duration:
- chronic
- Species:
- mouse
- System:
- respiratory system: lower respiratory tract
- Organ:
- other: lung > jejunum and liver
Justification for classification or non-classification
Additional information
Carcinogenicity: via oral route (target organ): respiratory: lung; digestive: jejunum; digestive: liver (depending on dose, most sensitive was lung).
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.